A new migraine drug could be nearing approval; gunshot victims face long-term risks

More phase 3 ubrogepant data published as FDA decision nears By Jake Remaly An acute treatment for migraine shows positive results in a phase 3 trial. Other news: Gunshot wound victims are at high risk for readmission Individuals who sustain gunshot wounds have an increased risk for rehospitalization years, and even decades, after their initial injury. FDA expands use of Toujeo to childhood type 1 diabetesThe new indication includes children as young as 6 years of age. FDA approves Tula system for recurrent pediatric ear infectionsThe system can be used in an office setting under local anesthesia. Higher risk of bipolar disorder, depression, anxiety found with autismThe study supports the importance of early and ongoing surveillance, the researchers said.   You can contact the MDedge Daily Medical News by emailing us at [email protected] or following us on Twitter at @MDedgeTweets.